Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs
- PMID: 3148473
- DOI: 10.1007/BF00637604
Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs
Abstract
The pharmacokinetics of Factor VIII was evaluated by mathematical modeling in a large-scale study in 62 haemophilia-A subjects, in whom 137 plasma Factor VIII-time curves were measured during single dose (n = 87) and repeated-dose (n = 47) treatments for prophylaxis or minor bleeding episodes. The pharmacokinetic parameters [mean (SD)] estimated from single-dose curves were: clearance 3.85 ml.h-1.kg-1, volume of distribution 58.2 ml.kg-1, mean residence time 15.9 h. Parameters calculated from repeated-dose curves were: clearance 3.93 ml.h-1.kg-1, volume of distribution 61.8 ml.kg-1, and half-life 12.2 h. In patients with mild haemophilia, pharmaco-statistical analysis revealed that the endogenous synthesis of Factor VIII was constant and was not influenced by the administration of exogenous Factor VIII. The coefficient of variation for intra-individual variability of Factor VIII kinetics (estimated according to the Standard Two-Stage method) was 20.7% in single-dose curves and 23.2% in repeated-dose curves.
Similar articles
-
A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.Ther Drug Monit. 2007 Feb;29(1):20-6. doi: 10.1097/FTD.0b013e3180311384. Ther Drug Monit. 2007. PMID: 17304146 Clinical Trial.
-
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.J Thromb Haemost. 2010 Apr;8(4):730-6. doi: 10.1111/j.1538-7836.2010.03757.x. J Thromb Haemost. 2010. PMID: 20398185 Free PMC article.
-
BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.Haemophilia. 2018 Sep;24(5):733-740. doi: 10.1111/hae.13561. Epub 2018 Jul 2. Haemophilia. 2018. PMID: 29963724
-
Clinical pharmacokinetics of factor VIII in patients with classic haemophilia.Clin Pharmacokinet. 1987 Dec;13(6):365-80. doi: 10.2165/00003088-198713060-00002. Clin Pharmacokinet. 1987. PMID: 3125001 Review.
-
Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels.Thromb Haemost. 2016 May 2;115(5):913-20. doi: 10.1160/TH15-08-0664. Epub 2016 Jan 21. Thromb Haemost. 2016. PMID: 26791493 Review.
Cited by
-
Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.J Pharm Sci. 2013 Jul;102(7):2380-94. doi: 10.1002/jps.23566. Epub 2013 Apr 25. J Pharm Sci. 2013. PMID: 23620343 Free PMC article.
-
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia.Clin Pharmacokinet. 2021 Jan;60(1):1-16. doi: 10.1007/s40262-020-00936-5. Clin Pharmacokinet. 2021. PMID: 32936401 Free PMC article. Review.
-
Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner.J Clin Transl Res. 2018 Feb 21;3(Suppl 2):351-357. eCollection 2018 Jul 30. J Clin Transl Res. 2018. PMID: 30873482 Free PMC article.
-
The History of Clotting Factor Concentrates Pharmacokinetics.J Clin Med. 2017 Mar 20;6(3):35. doi: 10.3390/jcm6030035. J Clin Med. 2017. PMID: 28335525 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical